# **MOP Rapid Test Cassette** (Whole Blood/Serum/Plasma) Package Insert

A rapid test for the qualitative detection of Morphine in human whole blood or serum or plasma. For medical and other professional in vitro diagnostic use only.

# [INTENDED USE]

The MOP Rapid Test Cassette (whole blood/serum/plasma) is a lateral flow chromatographic immunoassay for the detection of Opiate in whole blood or serum or plasma at a cut-off concentration of 40ng/ml. This test will detect other related compounds, please refer to the analytical specificity table in this package insert.

This assay provides only a qualitative, preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

## [SUMMARY]

Opioid analgesics comprise a large group of substances which control pain by depressing the CNS. Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the whole blood or serum or plasma for several days after an opiate dose.

The MOP Rapid Test Cassette is a rapid whole blood/serum/plasma screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Morphine in whole blood/serum/plasma. The MOP Rapid Test Cassette yields a positive result when Morphine in whole blood/serum/plasma reaches 40ng/ml.

#### PRINCIPLE

The MOP Rapid Test Cassette (whole blood/serum/plasma) is an immunoassay based on the principle of competitive binding. Drugs that may be present in the whole blood/serum/plasma specimen compete against the drug conjugate for binding sites on the antibody.

During testing, a whole blood/serum/plasma specimen migrates upward by capillary action .Morphine, if present in the whole blood/serum/plasma specimen below the cut-off level, will not saturate the binding sites of the antibody in the test. The antibody coated particles will then be captured by immobilized Morphine-protein conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Morphine level exceeds the cut-off level because it will saturate all the binding sites of anti-Morphine antibodies.

A drug-positive whole blood/serum/plasma specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative whole blood/serum/plasma specimen or a specimen containing a drug concentration less than the cut-off will generate a line in the test line region. To serve as a procedural control, a colored line will always appear at the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

# [REAGENTS]

The test contains mouse monoclonal anti-Morphine antibody coupled particles and Morphine-protein conjugate. A goat antibody is employed in the control line system.

#### [PRECAUTIONS]

- · For professional in vitro diagnostic use only. Do not use after the expiration date.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
- · Do not use test if pouch is damaged
- · Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens.
- · Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested
- The used test should be discarded according to local regulations.
- · Humidity and temperature can adversely affect results.

# STORAGE AND STABILITY

Store as packaged in the sealed pouch at room temperature or refrigerated (2-30°C). The test is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

# **SPECIMEN COLLECTION AND PREPARATION**

- . The MOP Rapid Test Cassette can be performed using whole blood (from venipuncture or fingerstick)/serum/plasma.
- To collect Fingerstick Whole Blood specimens:
- . Wash the patient's hand with soap and warm water or clean with an alcohol swab. Allow to dry. . Massage the hand without touching the puncture site by rubbing down the hand towards the
- fingertip of the middle or ring finger.
- Puncture the skin with a sterile lancet. Wipe away the first sign of blood.
- Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture
- . Add the Fingerstick whole blood to the test by using a capillary tube:
- Touch the end of the capillary tube to the blood until filled to approximately 40 μl. Avoid air
- · Place the bulb onto the top end of the capillary tube, then squeeze the bulb to dispense the Whole blood to the specimen area of the test cassette.
- · Testing should be performed immediately after the specimens have been collected. Do not leave the specimens at room temperature for prolonged periods. For long term storage, specimens should be kept below -20°C. Whole blood/serum/plasma collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood or serum or plasma specimens. Whole blood/serum/plasma collected by fingerstick should be tested immediately.
- · Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
- . If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiologic agents.

# [MATERIALS] · Test cassettes

# Materials Provided

Buffer

- Materials Required But Not Provided
  - Centrifuge

Package insert

- ·lancets (for fingerstick whole blood only)
- •Heparinized capillary tubes and dispensing bulb (for fingerstick whole blood only)


# [DIRECTIONS FOR USE]

Specimen collection containers

Allow the test, specimen, buffer and/or controls to reach room temperature (15-30°C) prior to

#### For serum or plasma specimen:

- 1. Bring the pouch to room temperature (15-30°C) before opening it. Remove the cassette from the sealed pouch and use it within one hour.
- 2. Place the cassette on a clean and level surface. Hold the dropper vertically and transfer 1 full drop of serum or plasma (approximately 40ul), then add 2 drops of buffer (approximately 80 µl) to the specimen well of the cassette, and then start the timer. Avoid trapping air bubbles in the specimen well. See illustration below
- 3. Wait for the colored line(s) to appear. Read the result at 5 minutes. Do not interpret the result after



#### For whole blood specimen:

- 1 Bring the pouch to room temperature before opening it. Remove the test cassette from the sealed pouch and use it as soon as possible.
- 2 Place the cassette on a clean and level surface.


#### For Venipuncture Whole blood specimen:

Hold the dropper vertically and transfer 1 drop of whole blood (approximately 40 ul) to the specimen well, then add  $\bf 2$  drops of buffer (approximately 80  $\mu$ l), and start the timer. See illustration below.

## For Fingerstick Whole blood specimen:

To use a capillary tube: Fill the capillary tube and transfer approximately 40µl of fingerstick Whole blood specimen to the specimen area of test cassette, then add 2 drops of buffer (approximately 80 μl) and start the timer. See illustration below

3 Wait for the colored line(s) to appear. Read results at 5 minutes. Do not interpret the result after 10



# [INTERPRETATION OF RESULTS]

(Please refer to the illustration above)

NEGATIVE:\* Two lines appear. One colored line should be in the control line region (C), and another apparent colored line should be in the test line region (T). This negative result indicates that the Morphine concentration is below the detectable cut-off level.

\*NOTE: The shade of color in the test line region (T) may vary, but it should be considered negative whenever there is even a faint colored line.

POSITIVE: One colored line appears in the control line region (C). No line appears in the test line region (T). This positive result indicates that the Morphine concentration exceeds the detectable cut-off level

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

# [QUALITY CONTROL]

A procedural control is included in the test. A colored line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance

## [ I IMI TATIONS]

- 1. The MOP Rapid Test Cassette (whole blood/serum/plasma) provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/ mass spectrometry (GC/MS) is the preferred confirmatory method.2
- 2. It is possible that technical or procedural errors, as well as other interfering substances in the whole blood or serum or plasma specimen may cause erroneous results.
- 3. A positive result indicates presence of the drug or its metabolites but does not indicate level of intoxication, administration route or concentration in whole blood or serum or plasma.
- 4. A negative result may not necessarily indicate drug-free whole blood/serum/plasma. Negative results can be obtained when drug is present but below the cut-off level of the test.

# 5. Test does not distinguish between drugs of abuse and certain medications.

## [EXPECTED VALUES]

This negative result indicates that the Morphinecon centration is below the detectable level of 40ng/ml. Positive result means the concentration of Morphine is above the level of 40ng/ml. The MOP Rapid Test Cassette has a sensitivity of 40ng/ml

# [PERFORMANCE CHARACTERISTICS]

## Accuracy

A side-by-side comparison was conducted using The MOP Rapid Test Cassette and GC/MS at the cut-off of 40ng/ml. Testing was performed on 90 clinical specimens previously collected from subjects present for Drug Screen Testing. The following results were tabulated:

# Clinic Result of Whole Blood

Method	Method		C/MS	Total Results
MOP Rapid Test	Results	Positive	Negative	Total Results

Cassette Positive		23	2	25	
	Negative	2	63	65	
Total Results		25	65	90	
% Agreement		92%	96.9%	95.6%	
OI: 1 P 1: 10 P1					

Clinic Result of Serum of Plasma						
Method		GC	/MS	Total Results		
MOD David Toot	Results	Positive	Negative	Total Results		
MOP Rapid Test Cassette	Positive	23	2	25		
	Negative	2	63	65		
Total Results		25	65	90		
% Agreement		92%	96.9%	95.6%		

#### Analytical Sensitivity

A drug-free whole blood/serum/plasma pool was spiked with MOP at the following concentrations of ±50%cutoff and 3x cutoff, the data are summarized below

#### For whole blood:

4-Acetamidophenol

i di wildie blood.							
MOP Concentration	Percent of Cut-off	_	Visual Result				
(ng/ml)	Percent of Cut-on	n	Negative	Positive			
0	0	30	30	0			
20	-50%	30	30	0			
40	Cut-off	30	15	15			
60	+50%	30	0	30			
120	3X	30	0	30			

For serum or plasma:					
MOP Concentration	Percent of Cut-off	n	Visual Result		
(ng/ml)			Negative	Positive	
0	0	30	30	0	
20	-50%	30	30	0	
40	Cut-off	30	15	15	
60	+50%	30	0	30	
120	3X	30	0	30	

#### Analytical Specificity

The following table lists compounds that are positively detected in whole blood/serum/plasma by The MOP Rapid Test Cassette (whole blood/serum/plasma) at 5 minutes.

Compound	Concentration (ng/ml)
Codeine	50
levorphanol	200
Morphine-3-β-D-Glucuronide	120
Ethylmorphine	500
Hydrocodone	5,000
Hydromorphone	300
6-Monoacethylmorphine	100
Norcodeine	500
Normorphone	5,000
Oxycodone	4,000
Oxymorphone	500
Procaine	1,500
Thebaine	500
Morphine	40

# Precision

A study was conducted at three volunteer by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens, containing no MOP and 50% MOP above and below the 40ng/ml cut-off was provided to each site. The following results were tabulated:

MOP Concentration	n	Sit	e A	Sit	e B	Site	e C
(ng/ml)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
20	10	8	2	9	1	9	1
60	10	1	9	1	9	2	8
Cross-Reactivity							

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free whole blood/serum/plasma or determine positive whole blood/serum/plasma. The following compounds show no cross-reactivity when tested with The MOP Rapid Test Cassette (whole blood/serum/plasma) at a concentration of 100 µg/ml

**β-Phenylethylamine** 

#### Non Cross-Reacting Compounds Creatinine loperamide

Acetophenetidin	Deoxycorticosterone	Maprotiline	Phenylpropanolamine
N-Acetylprocainamide	Dextromethorphan	Meperidine	Prednisone
Acetylsalicylic acid	Diazepam	Meprobamate	D,I-Propanolol
Aminopyrine	Diclofenac	Methadone	D-Propoxyphene
Amitryptyline	Diflunisal	Methoxyphenamine	D-Pseudoephedrine
Amobarbital	Digoxin	(+) 3,4-Methylenedioxy-	Quinidine
Amoxicillin	Diphenhydramine	amphetamine	Quinine
Ampicillin	Doxylamine	(+) 3,4-Methylenedioxy-	Ranitidine
I-Ascorbic acid	Ecgonine hydrochloride	methamphetamine	Salicylic acid
D,I-Amphetamine	Ecgonine methylester	Nalidixic acid	Secobarbital
Apomorphine	(-)-ψ-Ephedrine	Nalorphine	Serotonin
Aspartame	Erythromycin	Naloxone	(5-Hydroxytyramine)
Atropine	β-Estradiol	Naltrexone	Sulfamethazine
Benzilic acid	Estrone-3-sulfate	Naproxen	Sulindac
Benzoic acid	Ethyl-p-aminobenzoate	Niacinamide	Temazepam
Benzoylecgonine	Fenoprofen	Nifedipine	Tetracycline
Benzphetamine	Furosemide	Norethindrone	Tetrahydrocortisone,
Bilirubin	Gentisic acid	D-Norpropoxyphene	3-Acetate
(±) - Brompheniramine	Hemoglobin	Noscapine	Tetrahydrocortisone
Caffeine	Hydralazine	D,I-Octopamine	3-(β-D glucuronide)
Cannabidiol	Hydrochlorothiazide	Oxalic acid	Tetrahydrozoline
Chloralhydrate	Hydrocortisone	Oxazepam	Thiamine
Chloramphenicol	O-Hydroxyhippuric acid	Oxolinic acid	Thioridazine
Chlordiazepoxide	p-Hydroxy-	Oxymetazoline	D, I-Tyrosine
Chlorothiazide	methamphetamine	Papaverine	Tolbutamide
(±) Chlorpheniramine	3-Hydroxytyramine	Penicillin-G	Triamterene

Chlorpromazine Chlorquine Cholesterol Trifluoperazine Trimethoprim Trimipramine Ibuprofen Pentazocine Imipramine Pentobarbital Iproniazid Perphenazine Tryptamine D, I-Tryptophan Clomipramine (±) Isoproterenol Phencyclidine Clonidine Isoxsuprine
Cocaine hydrochloride Ketamine Phenelzine Phenobarbital Tyramine Ketoprofen labetalol Cortisone Phentermine Uric acid Verapamil Zomepirac β-Phenylethylamine (-) Cotinine I-Phenylephrine

4-Acetamidophenol Creatinine loperamide β-Phenylethylamine
Interfering Substances

The MOP Rapid Test Cassette (whole blood/serum/plasma) has been tested for possible interference from visibly hemolyzed and lipemic specimens. In addition, no interference was observed in specimens containing up to 100 mg/dl hemoglobin;up to 100 mg/dl bilirubin; and up to 200 mg/dl human serum albumin.

- [BIBLIOGRAPHY]

  1. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735.
- 2. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man.2nd Ed. Biomedical Publ., Davis, CA.

Number: 145319301 Effective date: 2017.06.22